Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy (EXOCEP2GER)
The Effects of EXOPULSE Mollii Suit on Motor Functions in Children With Cerebral Palsy (EXOCEP 2 GER)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hanover, Germany
- Medizinische Hochschule Hannover (MHH)
-
-
Bavaria
-
Traunstein, Bavaria, Germany
- Pohlig GmbH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients will be included if they
- are between 5 and 12 years of age.
- have a clinical diagnosis of unilateraal or bilateral spastic CP by birth [15].
- have a PBS score between a minimum of 15 and a maxmimum of 44 points.
- are able to walk freely, with slight limitation or using ancillary equipment's (GMFCS score ≤3) [49].
- are German speakers, able to understand verbal instructions.
- have spasticity with a score of at least 1+ on the MAS
Exclusion Criteria:
Patients will not be included if they
- are included in another research protocol during the study period.
- are unable to undergo clinical procedures for the study purposes due to geographical or social reasons.
- have a cardiac stimulator, a ventriculoperitoneal shunt, intrathecal baclofen pump.
- have a change in their pharmacological therapy over the last three months or are planning to do so during the study.
- suffer from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain).
- have a body mass index above 35 kg/m2,
- have contraindications to wearing Exopulse Mollii Suit, receive a medical device other than Exopulse Mollii during the study period.
- have received botulinum toxin (botox) therapy in the last 3 months before the start of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active Stimulation
Active sessions will last 1 hour of stimulation per day for 2 weeks.
The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds.
|
Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit.
The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body.
The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
|
|
Sham Comparator: Sham Stimulation
In the sham condition, subjects will be asked to wear the device for 1 hour per day for 2 weeks.
During 1 hour use per day, the actual stimulation will last only 1 minute and then will shut off.
|
In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Pediatric Balance Scale (PBS)
Time Frame: Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
Pediatric patients with CP, the PBS has a minimum detectable change (MDC) of 1.59 for the total score and 0.79 (static) and 0.96 (dynamic) for the subscores.
Furthermore, the PBS has a minimally clinically important difference (MCID) for the cohort mentioned of 5.83 for the otal score and 2.92 (static) and 2.92 (dynamic) for the subscores.
|
Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Modified Ashworth Scale (MAS)
Time Frame: Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
The modified Ashworth Scale measures spasticity in patients with lesions of the Central Nervous System.
It tests resistance to passive movement in a joint with varying degrees of velocity.
Scores range from 0-4 with 5 choices.
A score of 1 indicates no resistance, and a 5 indicates rigidity.
|
Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
|
Changes in Timed Up and Go (TUG)
Time Frame: Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
In the chair with his/her back against the chair back.
On the command "go", the patient rises from the chair, walks 3Visit 1 = Immediately before and after first 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = 4 weeks after visit 1. Immediately before and after first 1h stimulation; Visit 4 = 6 weeks after visit 1 meters at a comfortable and safe pace, turns, walks back to the chair and sits down.
Timing begins at the instruction "go" and stops when the patient is seated.
|
Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Diary
Time Frame: Visit 1; Visit 2 = 2 weeks after visit 1; Visit 3 = 4 weeks after visit 1. Visit 4 = 6 weeks after visit 1
|
4. Patient Diary A patient diary is provided to patiets to record information during the 14-day homeuse phase.
If the child is not able to do this him/herself, the parent or cargicer can support this process.
The use of the Exopulse Mollii Suit should be recorded, whether the stimulation duration of 1 hour is adhered every day.
In addition, comfort/satisfaction, pain/discomfort and possible incidents such as mild adverse events should be documented.
|
Visit 1; Visit 2 = 2 weeks after visit 1; Visit 3 = 4 weeks after visit 1. Visit 4 = 6 weeks after visit 1
|
|
Blinding Questionnaire
Time Frame: Visit 2 = 2 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
Evaluation of patient's blinding to the type of stimulation will be performed by asking for their perception which treatment they received: "(a) Treatment/ (b) Placebo/ (c) I don' know" and "if (c) I don't know" which they would by chance choose "(a) Treatment/ (b) Placebo.
|
Visit 2 = 2 weeks after visit 1; Visit 4 = 6 weeks after visit 1
|
|
Changes in Functional Gait Assessment (FGA)
Time Frame: Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1. ; Visit 4 = 6 weeks after visit 1
|
(optional)
|
Visit 1 = Immediately before and after 1h stimulation; Visit 2 = 2 weeks after visit 1; Visit 3 = Immediately before and after 1h stimulation, 4 weeks after visit 1. ; Visit 4 = 6 weeks after visit 1
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Musculoskeletal Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Muscular Diseases
- Muscle Hypertonia
- Neuromuscular Manifestations
- Mental Disorders
- Brain Damage, Chronic
- Paralysis
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Muscle Spasticity
- Somatoform Disorders
- Cerebral Palsy
- Quadriplegia
- Hemiplegia
Other Study ID Numbers
Other Study ID Numbers
- PS00011278C-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.